NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Health Information Services · USD

Certara, Inc. (CERT) Stock Analysis

Certara, Inc. (CERT) is a Health Information Services stock listed on NASDAQ and quoted in US Dollar.

CERT

$7.94

−$0.19 (−2.34%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CERT with… →

CERT Key Statistics

As of Sep 4, 2026
Trading
Open
$8.02
Previous Close
$8.13
Day's Range
7.91–8.05
52-Week Range
4.45–13.88
Volume
1.27M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.41
Valuation
Market Cap
$1.21B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
20.32
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.87
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.14
Financials (FY)
Revenue (FY)
$418.84M+8.75%
Net Income (FY)
−$1.60M
Profit marginThe share of revenue left as profit after all costs and taxes.
−16.22%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
152.54M
1-Year Return
−24.95%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
3.89M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CERT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−9.88%
2025−17.28%
2024−39.45%
2023+9.46%
2022−43.46%
2021−15.72%
2020 (partial year)−11.45%

As of September 4, 2026.

CERT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$418.84M−$1.60M−0.4%
2024$385.15M−$12.05M−3.1%
2023$354.34M−$55.36M−15.6%
2022$335.64M$14.73M4.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$418.84M$257.71M$21.02M−$1.60M−0.4%
2024$385.15M$230.63M−$1.73M−$12.05M−3.1%
2023$354.34M$213.32M$6.21M−$55.36M−15.6%
2022$335.64M$203.07M$32.52M$14.73M4.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CERT Valuation vs Health Information Services Median

Median of 53 stocks
MetricCERTHealth Information Services medianvs median
P/S ratio2.872.668% above
Profit margin−16.22%0.00%16.2 pts below

Medians across 53 Health Information Services stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Certara, Inc. (CERT) is capitalised at $1.21B on the latest close. It is classified in the Health Information Services industry, within the Healthcare sector. The company reports 1,515 employees.

The most recent close on file for CERT is $7.94, dated September 4, 2026. That is −$0.19 (−2.34%) against the previous close. Over the past 52 weeks the price has ranged from $4.45 to $13.88. The latest close sits 78.43% above that 52-week low.

Financial Health

In fiscal 2025, Certara, Inc. reported revenue of $418.84M. That is +8.75% against the prior fiscal year, when revenue was $385.15M. The same year closed with a net loss of $1.60M. The reported profit margin is −16.22%. That is 16.2 percentage points below the Health Information Services median of 0%. Earnings per share on a trailing basis come to −0.14.

Across the 4 fiscal years on file, revenue moves from $335.64M in 2022 to $418.84M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 20.32. Measured against sales, the shares trade at 2.87 times revenue. On price-to-sales that is 8.01% above the Health Information Services median of 2.66. 53 Health Information Services companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.41. Annualized volatility over the trailing 5 years is 55.91%. The trailing one-year price return is −24.95%. Measured over 5 years, that is −26.80% a year compounded.

Growth & Income

The record shows no dividend for CERT.

So far in 2026 the price is −9.88%. The strongest complete calendar year on file is 2023 at +9.46%; the weakest is 2022 at −43.46%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Certara, Inc. (CERT) operates in the Health Information Services industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Certara, Inc. CERT $1.21B —
Veeva Systems Inc. VEEV $44.54B 45.0
BrightSpring Health Services, Inc. BTSG $12.02B 54.7
Tempus AI, Inc. TEM $11.66B —

The Health Information Services industry average P/E ratio is 41.1x. Certara, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Health Information Services Stocks

VEEV

Veeva Systems Inc.

$44.54B

 BTSG

BrightSpring Health Services, Inc.

$12.02B

 TEM

Tempus AI, Inc.

$11.66B

 HQY

HealthEquity, Inc.

$7.95B

 HNGE

Hinge Health, Inc.

$7.45B

 WAY

Waystar Holding Corp.

$4.81B
View all Health Information Services stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Certara, Inc.

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Visit website →